慢性肾脏病患者应用钠-葡萄糖协同转运蛋白2抑制剂的中国专家共识 - Suppr | 超能文献

相似文献

1

Chinese expert consensus on the clinical application of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease.慢性肾脏病患者应用钠-葡萄糖协同转运蛋白2抑制剂的中国专家共识

Chin Med J (Engl). 2024 Jun 5;137(11):1264-1266. doi: 10.1097/CM9.0000000000003145. Epub 2024 May 13.

2

Advancing American Kidney Health and the Role of Sodium-Glucose Cotransporter-2 Inhibitors: A Missed Opportunity.推进美国肾脏健康与钠-葡萄糖协同转运蛋白2抑制剂的作用：一个错失的机会

Clin J Am Soc Nephrol. 2021 Oct;16(10):1584-1586. doi: 10.2215/CJN.05450421. Epub 2021 Jun 16.

3

Sodium-glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease.用于慢性肾脏病合并心力衰竭的钠-葡萄糖协同转运蛋白2抑制剂

ESC Heart Fail. 2022 Oct;9(5):3661-3662. doi: 10.1002/ehf2.14095. Epub 2022 Jul 25.

4

Sodium-glucose cotransporter-2 inhibitors: Use in patients with chronic kidney disease.钠-葡萄糖协同转运蛋白2抑制剂：在慢性肾脏病患者中的应用

Can Fam Physician. 2022 Oct;68(10):753. doi: 10.46747/cfp.6810753.

5

Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.重点更新：心力衰竭和/或慢性肾脏病患者的 SGLT2 抑制剂。

Ann Pharmacother. 2021 Feb;55(2):252-260. doi: 10.1177/1060028020934001. Epub 2020 Jun 13.

6

[Clinical and practical management of sodium-glucose cotransporter type 2 inhibitors in patients with chronic kidney disease].[慢性肾脏病患者中钠-葡萄糖协同转运蛋白2抑制剂的临床与实际管理]

Semergen. 2023 Jun;49 Suppl 1:102020. doi: 10.1016/j.semerg.2023.102020.

7

Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.综述探讨钠-葡萄糖共转运蛋白 2 抑制剂在糖尿病和非糖尿病慢性肾脏病患者中的肾保护机制。

Front Endocrinol (Lausanne). 2023 Dec 20;14:1281107. doi: 10.3389/fendo.2023.1281107. eCollection 2023.

8

Finding the sweet spot in managing diabetes with coronary artery disease and chronic kidney disease: Pharmacotherapy pearls with a focus on sodium-glucose cotransporter-2 inhibitors.在合并冠状动脉疾病和慢性肾脏病的糖尿病管理中找到最佳平衡点：聚焦钠-葡萄糖协同转运蛋白2抑制剂的药物治疗要点

Can Fam Physician. 2020 May;66(5):341-346.

9

Effects of sodium glucose co-transporter 2 inhibitors on the kidney.钠-葡萄糖协同转运蛋白2抑制剂对肾脏的影响。

Diab Vasc Dis Res. 2018 Sep;15(5):375-386. doi: 10.1177/1479164118783756. Epub 2018 Jul 2.

10

Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology.中国 2 型糖尿病合并心血管疾病或慢性肾脏病患者的降糖药物治疗专家共识。中华医学会糖尿病学分会和中华医学会内分泌学分会报告。

Diabetes Metab Res Rev. 2021 May;37(4):e3416. doi: 10.1002/dmrr.3416. Epub 2020 Nov 23.